Skip to content
Awesome – Lifestyle
Author:
Atossa Therapeutics Inc
Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women
May 6, 2026
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome
May 4, 2026
Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference
March 12, 2026
←
Previous Page
1
2